Gilead Sciences CEO Files Form 144 to Sell $18.8M in Stock

Executive Summary

On November 4, 2026, Daniel Patrick O'Day, Chairman and CEO of Gilead Sciences, Inc. ($GILD), filed Form 144 indicating an intent to sell 112,429 shares of common stock with an aggregate market value of approximately $18.83 million.

Transaction & Plan Details

• Nature of Acquisition: The securities to be sold are acquired via the exercise of stock options for cash from the issuer.
• Rule 10b5-1 Plan: The proposed sale is executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on February 25, 2026.
• Recent Prior Sales: Over the preceding three months, the insider sold an aggregate of 60,881 shares for gross proceeds of approximately $9.78 million under the same 10b5-1 program.
• Broker: Morgan Stanley Smith Barney LLC Executive Financial Services.

Market Impact & Significance

Trading significance is rated as Medium. Although the dollar volume ($18.8M) is notable, the sale represents less than 0.01% of the 1.24 billion outstanding common shares and is executed under a pre-established Rule 10b5-1 plan originating from option exercises over a planned multi-month execution schedule.